LeMaitre Vascular, Inc. (LMAT): Price and Financial Metrics

LeMaitre Vascular, Inc. (LMAT): $64.91

0.89 (+1.39%)

POWR Rating

Component Grades








Add LMAT to Watchlist
Sign Up

LMAT Price/Volume Stats

Current price $64.91 52-week high $68.06
Prev. close $64.02 52-week low $40.82
Day low $63.38 Volume 132,400
Day high $65.35 Avg. volume 96,650
50-day MA $57.46 Dividend yield 0.89%
200-day MA $50.42 Market Cap 1.44B

LMAT Stock Price Chart Interactive Chart >


  • LMAT scores best on the Growth dimension, with a Growth rank ahead of 94.42% of US stocks.
  • The strongest trend for LMAT is in Value, which has been heading down over the past 179 days.
  • LMAT's current lowest rank is in the Momentum metric (where it is better than 15.05% of US stocks).

LMAT Stock Summary

  • With a price/earnings ratio of 64.53, LEMAITRE VASCULAR INC P/E ratio is greater than that of about 91.63% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for LMAT is currently 58.04, higher than 93.47% of US stocks with positive operating cash flow.
  • LMAT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 11.63% of US stocks.
  • If you're looking for stocks that are quantitatively similar to LEMAITRE VASCULAR INC, a group of peers worth examining would be ATRI, MMSI, SHYF, INTT, and KVHI.
  • Visit LMAT's SEC page to see the company's official filings. To visit the company's web site, go to www.lemaitre.com.

LMAT Valuation Summary

  • LMAT's price/earnings ratio is 65.5; this is 171.78% higher than that of the median Healthcare stock.
  • Over the past 202 months, LMAT's EV/EBIT ratio has gone down 233.3.

Below are key valuation metrics over time for LMAT.

Stock Date P/S P/B P/E EV/EBIT
LMAT 2023-05-23 8.0 4.9 65.5 49.2
LMAT 2023-05-22 8.1 5.0 66.5 49.9
LMAT 2023-05-19 8.2 5.0 66.9 50.2
LMAT 2023-05-18 8.3 5.1 67.8 50.9
LMAT 2023-05-17 8.4 5.2 68.5 51.4
LMAT 2023-05-16 8.4 5.2 69.1 51.9

LMAT Growth Metrics

    Its year over year revenue growth rate is now at 17.38%.
  • Its year over year net cashflow from operations growth rate is now at -14.98%.
  • Its 5 year net income to common stockholders growth rate is now at 51.12%.
Over the past 33 months, LMAT's revenue has gone up $42,968,000.

The table below shows LMAT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 160.2 26.357 21.184
2022-06-30 159.54 33.09 22.232
2022-03-31 158.102 33.739 27.016
2021-12-31 154.424 35.102 26.907
2021-09-30 152.469 44.198 27.765
2021-06-30 150.517 44.235 28.774

LMAT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LMAT has a Quality Grade of B, ranking ahead of 84.43% of graded US stocks.
  • LMAT's asset turnover comes in at 0.589 -- ranking 73rd of 186 Medical Equipment stocks.
  • ISRG, SYK, and KIDS are the stocks whose asset turnover ratios are most correlated with LMAT.

The table below shows LMAT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.589 0.655 0.287
2021-06-30 0.597 0.649 0.299
2021-03-31 0.530 0.653 0.241
2020-12-31 0.542 0.654 0.220
2020-09-30 0.548 0.657 0.196
2020-06-30 0.574 0.677 0.177

LMAT Price Target

For more insight on analysts targets of LMAT, see our LMAT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $66.14 Average Broker Recommendation 1.5 (Moderate Buy)

LeMaitre Vascular, Inc. (LMAT) Company Bio

LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease. The company was founded in 1983 and is based in Burlington, Massachusetts.

LMAT Latest News Stream

Event/Time News Detail
Loading, please wait...

LMAT Latest Social Stream

Loading social stream, please wait...

View Full LMAT Social Stream

Latest LMAT News From Around the Web

Below are the latest news stories about LEMAITRE VASCULAR INC that investors may wish to consider to help them evaluate LMAT as an investment opportunity.

Is This Healthcare Stock a Buy for Dividend Growth Investors?

One stock that has worked out considerably well for its investors is LeMaitre Vascular (NASDAQ: LMAT). Let's elaborate on the medical device company's fundamentals and valuation to make a judgment. LeMaitre Vascular has stayed the course in vascular medical devices and resisted the urge to branch out into the unknown.

Yahoo | May 17, 2023

LeMaitre Vascular goes ex-dividend tomorrow


Seeking Alpha | May 15, 2023

Q1 2023 Aziyo Biologics Inc Earnings Call

Q1 2023 Aziyo Biologics Inc Earnings Call

Yahoo | May 11, 2023

What Makes LeMaitre Vascular (LMAT) a Strong Momentum Stock: Buy Now?

Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | May 10, 2023

Is Now The Time To Look At Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...

Yahoo | May 4, 2023

Read More 'LMAT' Stories Here

LMAT Price Returns

1-mo -0.27%
3-mo 28.67%
6-mo 41.79%
1-year 43.62%
3-year 150.39%
5-year 97.14%
YTD 41.76%
2022 -7.40%
2021 25.10%
2020 14.09%
2019 53.77%
2018 -25.13%

LMAT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full LMAT Dividend History

Continue Researching LMAT

Here are a few links from around the web to help you further your research on Lemaitre Vascular Inc's stock as an investment opportunity:

Lemaitre Vascular Inc (LMAT) Stock Price | Nasdaq
Lemaitre Vascular Inc (LMAT) Stock Quote, History and News - Yahoo Finance
Lemaitre Vascular Inc (LMAT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!